PASG חוב כולל להון Passage Bio Corp

Passage Bio, Inc. (PASG) relies on the development of innovative AAV vectors to restore brain function, ensuring significant pricing power within the rare disease niche. Business prospects are tied to regulatory approvals and the safety of gene protocols. Within a closed pediatric environment, the total debt-to-equity ratio stands at 0.00, as clearly demonstrated by the historical price action of this financial metric.

This ratio measures the proportion of borrowed funds to equity, determining the degree of financial leverage and the overall resilience of the balance sheet to external shocks. For Passage Bio, Inc. (PASG), which invests in costly CNS gene therapy developments, the total debt-to-equity trend reflects a balance between credit load and the resources required to implement unique treatments for rare diseases.